SCHEMBL1298412

SCHEMBL1298412

Nc1ccc(-c2ccc3ccccc3n2)cc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 13/20 1.00
RAB9A P51151 13/20 1.00
MEN1 O00255 5/20 1.00
KMT2A Q03164 5/20 1.00
KDM4E B2RXH2 9/20 0.96
ALDH1A1 P00352 9/20 0.96
SMN1; SMN2 Q16637 8/20 0.96
MAPT P10636 8/20 0.96
HPGD P15428 5/20 0.96
HSD17B10 Q99714 5/20 0.96
TP53 P04637 4/20 0.96
PKM P14618 3/20 0.96
CYP3A4 P08684 2/20 0.96
GMNN O75496 1/20 0.96
THPO P40225 1/20 0.96
BLM P54132 1/20 0.96
PMP22 Q01453 1/20 0.96
AR P10275 2/20 0.67
CYP1A2 P05177 1/20 0.63
CYP2D6 P10635 1/20 0.63

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL483422 0.98 KDM4E (1.00) NPC1RAB9AMEN1KMT2AKDM4E
Hydrochloric Acid SCHEMBL29693306 0.98 KDM4E (1.00) NPC1RAB9AMEN1KMT2AKDM4E
Hydrochloric Acid SCHEMBL2487558 0.98 KDM4E (1.00) NPC1RAB9AMEN1KMT2AKDM4E
SCHEMBL12402712 0.90 NPC1 (0.81) NPC1RAB9AMEN1KMT2AKDM4E
SCHEMBL12112870 0.89 RAB9A (0.80) NPC1RAB9AMEN1KMT2AKDM4E
SCHEMBL31571831 0.83 RAB9A (0.71) NPC1RAB9AMEN1KMT2AKDM4E
SCHEMBL706884 0.83 RAB9A (0.71) NPC1RAB9AMEN1KMT2AKDM4E
2-Phenylquinoline SCHEMBL29399739 0.83 RAB9A (0.73) NPC1RAB9AMEN1KMT2AKDM4E
2-Phenylquinoline SCHEMBL44999 0.83 RAB9A (0.73) NPC1RAB9AMEN1KMT2AKDM4E
2-Phenylquinoline SCHEMBL6858671 0.81 RAB9A (0.70) NPC1RAB9AMEN1KMT2AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2640703-A1 HETEROCYCLIC COMPOUNDS AS IMAGING PROBES OF TAU PATHOLOGY GE Healthcare UK Limited (GB) 2013-09-25 EP claimed
US-20130236395-A1 HETEROCYCLIC COMPOUNDS AS IMAGING PROBES OF TAU PATHOLOGY GE HEALTHCARE LIMITED (GB) 2013-09-12 US claimed
CN-103298789-A Heterocyclic compounds as imaging probes of tau pathology GE HEALTHCARE LTD 2013-09-11 CN claimed
WO-2012067863-A1 HETEROCYCLIC COMPOUNDS AS IMAGING PROBES OF TAU PATHOLOGY GE HEALTHCARE LIMITED (GB) 2012-05-24 WO claimed
US-7118730-B2 Quinoline derivative as diagnostic probe for disease with tau protein accumulation BF RESEARCH INSTITUTE, INC. (JP) 2006-10-10 US claimed
US-20250340547-A1 NOVEL COMPOUNDS FOR IMAGING TAU PROTEINS THAT ACCUMULATE IN THE BRAIN NATIONAL INSTITUTES FOR QUANTUM AND RADIOLOGICAL SCIENCE AND TECHNOLOGY (JP) 2025-11-06 US disclosed
US-12195454-B2 Compounds for imaging tau proteins that accumulate in the brain NATIONAL INSTITUTES FOR QUANTUM AND RADIOLOGICAL SCIENCE AND TECHNOLOGY (JP) 2025-01-14 US disclosed
CN-117987155-A Low-temperature curing liquid crystal aligning agent, liquid crystal aligning film, preparation method of liquid crystal aligning film and liquid crystal display element 深圳市道尔顿电子材料股份有限公司 2024-05-07 CN disclosed
US-20240083893-A1 COMPOUNDS FOR IMAGING TAU PROTEINS THAT ACCUMULATE IN THE BRAIN NATIONAL INSTITUTES FOR QUANTUM AND RADIOLOGICAL SCIENCE AND TECHNOLOGY (JP) 2024-03-14 US disclosed
US-11912699-B2 Tau-protein targeting compounds and associated ARVINAS OPERATIONS, INC. (US) 2024-02-27 US disclosed
US-20230183209-A1 CEREBLON LIGANDS AND BIFUNCTIONAL COMPOUNDS COMPRISING THE SAME ARVINAS OPERATIONS, INC. (US) 2023-06-15 US disclosed
US-11667628-B2 Compounds for imaging tau proteins that accumulate in brain NATIONAL INSTITUTES FOR QUANTUM AND RADIOLOGICAL SCIENCE AND TECHNOLOGY (JP) 2023-06-06 US disclosed
WO-2011119565-A1 IMAGING AGENTS FOR DETECTING NEUROLOGICAL DISORDERS SIEMENS MEDICAL SOLUTIONS USA, INC. (US) 2011-09-29 WO disclosed
WO-2011115513-A2 A CYTOSINE ANALOGUE, A METHOD OF PREPARATION OF A CYTOSINE ANALOGUE, A DNA METHYLTRANSFERASE 1 INHIBITOR, A METHOD FOR DNA METHYLATION INHIBITION, THE USE OF THE ANALOGUE IN THE TREATMENT OF DISEASES ASSOCIATED WITH DEVIATIONS FROM NORMAL DNA METHYLATION INSTYTUT CHEMII BIOORGANICZNEJ PAN (PL) 2011-09-22 WO disclosed
US-7118730-B2 Quinoline derivative as diagnostic probe for disease with tau protein accumulation BF RESEARCH INSTITUTE, INC. (JP) 2006-10-10 US disclosed
US-20050260126-A1 Diagnostic probes and remedies for diseases with accumulation of prion protein, and stains for prion protein BF RESEARCH INSTITUTE (JP) 2005-11-24 US disclosed
EP-1574500-A1 QUINOLINE DERIVATIVE AS DIAGNOSTIC PROBE FOR DISEASE WITH TAU PROTEIN ACCUMULATION BF Research Institute, Inc. (JP) 2005-09-14 EP disclosed
US-20050009865-A1 Quinoline derivative as diagnostic probe for disease with tau protein accumulation BF RESEARCH INSTITUTE, INC. (JP) 2005-01-13 US disclosed
EP-0168812-A1 4-Amino-2-phenyl quinolines, methods and intermediates for their preparation and medicaments containing them F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) 1986-01-22 EP disclosed
EP-0087709-A1 N,N',N\"-triaryl-1,2,3-triaminopropane derivatives, process for their preparation and their use as intermediates HOECHST AKTIENGESELLSCHAFT (DE) 1983-09-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230183209-A1 CEREBLON LIGANDS AND BIFUNCTIONAL COMPOUNDS COMPRISING THE SAME CRBN, CBL, MDM2 NPC1 3571/4885RAB9A 3202/4885MEN1 727/4885
US-11912699-B2 Tau-protein targeting compounds and associated MAPT, VHL, CRBN NPC1 2550/4885RAB9A 1429/4885MEN1 1944/4885
US-20240083893-A1 COMPOUNDS FOR IMAGING TAU PROTEINS THAT ACCUMULATE IN THE BRAIN MAPT, FABP7, HTT NPC1 1911/4885RAB9A 1120/4885MEN1 4010/4885
US-12195454-B2 Compounds for imaging tau proteins that accumulate in the brain MAPT, FABP7, HTT NPC1 1911/4885RAB9A 1120/4885MEN1 4010/4885
US-20050009865-A1 Quinoline derivative as diagnostic probe for disease with tau protein accumulation MAPT, APP, PSEN1 NPC1 332/4885RAB9A 2676/4885MEN1 1854/4885
US-20050260126-A1 Diagnostic probes and remedies for diseases with accumulation of prion protein, and stains for prion protein PRNP, PRPH, PCNP NPC1 147/4885RAB9A 1787/4885MEN1 3565/4885
US-11667628-B2 Compounds for imaging tau proteins that accumulate in brain MAPT, FABP7, HTT NPC1 1841/4885RAB9A 1119/4885MEN1 3842/4885
US-20250340547-A1 NOVEL COMPOUNDS FOR IMAGING TAU PROTEINS THAT ACCUMULATE IN THE BRAIN MAPT, FABP7, HTT NPC1 2035/4885RAB9A 948/4885MEN1 4288/4885
US-20130236395-A1 HETEROCYCLIC COMPOUNDS AS IMAGING PROBES OF TAU PATHOLOGY MAPT, PSEN1, PSEN2 NPC1 127/4885RAB9A 1703/4885MEN1 513/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.